AAIC 2017: An Update on Scientific Advances and Clinical Strategies in Alzheimer’s Disease from the Alzheimer’s Association International Conference® 2017 (AAIC®)

The Alzheimer’s Association International Conference® 2017 (AAIC®) was held in London, England, July 16-20, 2017. As the largest international meeting dedicated to advancing dementia science, AAIC unites leaders from more than 70 countries to discuss the latest dementia study results and theories. In this activity, 2 experts summarize the key learnings from this year’s conference.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of health care professionals responsible for the diagnosis, treatment, or management of patients with Alzheimer’s disease.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

  1. Identify therapies in development for the treatment of AD

  2. Analyze advances in the development of biomarkers to diagnose AD and to evaluate and monitor interventions

FACULTY

Lawrence S. Honig, MD, PhD, FAAN
Professor of Neurology at CUMC
Columbia University College of Physicians and Surgeons
New York, New York

Mary Sano, PhD
Director
Alzheimer’s Disease Research Center
Professor
Department of Psychiatry
Associate Dean
Clinical Research
Icahn School of Medicine at Mount Sinai
New York, New York
Director of Research
James J. Peters VA Medical Center
Bronx, New York

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or PresenterRelationship Identified With:

Lawrence S. Honig, MD, PhD, FAAN

Grant/Research Support: AbbVie Inc., AstraZeneca, Bristol-Myers Squibb Company, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffman-La Roche Ltd, Genentech, Inc., Pfizer Inc, TauRx

Mary Sano, PhD

Consultant/Advisor: AZTherapies, Inc., Biogen, F. Hoffman-La Roche Ltd, Recruitment Partners, Takeda Pharmaceutical Company Limited, VTV Therapeutics

Non-faculty: Lyerka Miller, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by independent educational grants from AbbVie Inc. and GE Healthcare Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu. Additional information on the process of converting AMA PRA Category 1 Credit™ to ECMECs® can be found at: www.eaccme.eu.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Miller Medical Communications, LLC., AbbVie Inc. and GE Healthcare Inc., do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit(s)™
  • 0.75 Non-physician
Course opens: 
10/25/2017
Course expires: 
10/24/2018
Rating: 
0

Available Credit

  • 0.75 AMA PRA Category 1 Credit(s)™
  • 0.75 Non-physician

Accreditation Period

Course opens: 
10/25/2017
Course expires: 
10/24/2018
Please login or register to take this course.